MARKET

KTRA

KTRA

Kintara Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.360
+0.010
+0.73%
After Hours: 1.350 -0.01 -0.74% 17:27 11/25 EST
OPEN
1.340
PREV CLOSE
1.350
HIGH
1.370
LOW
1.290
VOLUME
313.99K
TURNOVER
--
52 WEEK HIGH
1.950
52 WEEK LOW
0.3800
MARKET CAP
33.54M
P/E (TTM)
-0.6846
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Medigus, Aptevo Therapeutics leads healthcare gainers; MeiraGTx Holdings, Kintara Therapeutics among major losers
Gainers: Medigus (MDGS) +30%, Aptevo Therapeutics (APVO) +29%, Corcept Therapeutics (CORT) +23%, Opiant Pharmaceuticals (OPNT) +15%, Aquestive Therapeutics (AQST) +11%.Losers: MeiraGTx Holdings (MGTX) -11%, Kintara Therapeutics (KTRA) -10%, Berkeley Lights (BLI) -10%, Kazia Therapeutics (KZIA) -8%, Immutep (IMMP) -7%.
Seekingalpha · 11/19 16:00
Kintara Therapeutics reports VAL-083 interim data for the treatment of glioblastoma multiforme
Kintara Therapeutics (KTRA) announces interim data from its two Phase 2 trials of VAL-083, the Company's lead compound for the treatment of glioblastoma multiforme ((GBM)).In newly-diagnosed receiving VAL-083 as adjuvant therapy, 27
Seekingalpha · 11/19 13:49
LB, YY, BERY and NKLA among premarket gainers
Phoenix New Media (FENG) +62% after announcing special distribution.Hudson Capital (HUSN) +37%.Aptevo Therapeutics (APVO) +31% following a disclosure that 42.5% shareholder Tang Capital Partners offered to buy the remaining shares for $50/share in cash.Corcept
Seekingalpha · 11/19 13:29
Kintara Therapeutics Reports 10 Months Progression-Free Survival In Newly-Diagnosed MGMT-Unmethylated GBM From Ongoing MD Anderson Cancer Center Phase 2 Study
Kintara Therapeutics Reports 10 Months Progression-Free Survival in Newly-Diagnosed MGMT-unmethylated GBM from Ongoing MD Anderson Cancer Center Phase 2 Study SAN DIEGO, Nov. 19, 2020 /PRNewswire/
Benzinga · 11/19 13:06
The Week Ahead In Biotech: The Vaccine Updates, Drug Presentations, And FDA Decisions That Will Move The Markets
Biotech stocks advanced in the week ended Nov. 13 amid a vaccine news flow-induced rally that also lifted the broader market.
Benzinga · 11/15 15:14
Kintara Therapeutics Q1 EPS $(1.33) Down From $(0.21) YoY
Kintara Therapeutics (NASDAQ:KTRA) reported quarterly losses of $(1.33) per share. This is a 533.33 percent decrease over losses of $(0.21) per share from the same period last year.
Benzinga · 11/13 13:08
KTRA: Merger Complete
By John Vandermosten, CFA NASDAQ:KTRA READ THE FULL KTRA RESEARCH REPORT Since Our Initiation Since our initiation on September 9th, Kintara Therapeutics Inc. (NASDAQ:KTRA) has reported 2020 financial and operational results in a press release and in its 10-K for the fiscal year ending June 30, 2020. The company also announced notification of a Small Business Technology Transfer grant to study
Zacks Small Cap Research · 10/12 11:45
3 “Strong Buy” Healthcare Stocks Under $5 That Could Go Boom
Since 2019, the healthcare sector has been bracing for the wild ride that would be the election year. However, according to some Street pros, 2021 is looking a lot like 2009, and this could actually be a good thing for the space.“[We] think 2021 will play out very similarly to 2009 for the health care
TipRanks · 10/01 19:30
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of KTRA. Analyze the recent business situations of Kintara Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average KTRA stock price target is 4.250 with a high estimate of 6.00 and a low estimate of 3.000.
EPS
Institutional Holdings
Institutions: 22
Institutional Holdings: 373.32K
% Owned: 1.51%
Shares Outstanding: 24.66M
TypeInstitutionsShares
Increased
1
80.78K
New
12
36.71K
Decreased
1
2.86K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.74%
Pharmaceuticals & Medical Research
+0.82%
Key Executives
Chairman/Independent Director
Robert Hoffman
President/Chief Executive Officer/Director
Saiid Zarrabian
Chief Financial Officer
Scott Praill
Chief Scientific Officer
Dennis Brown
Director
John Liatos
Director
Keith Murphy
Independent Director
Robert Toth
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About KTRA
Kintara Therapeutics Inc, formerly DelMar Pharmaceuticals, Inc., is a clinical-stage drug development company focused on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), and potentially other solid tumors, including ovarian cancer, non-small cell lung cancer (NSCLC) and diffuse intrinsic pontine glioma (DIPG). VAL-083 is being evaluated in a Phase II clinical trial for the treatment of GBM. In addition to its clinical development activities in the United States, the Company has obtained certain commercial rights to VAL-083 in China where it is approved as a chemotherapy for the treatment of chronic myelogenous leukemia (CML) and lung cancer. AL-083 is a small-molecule, a deoxyribonucleic acid (DNA) targeting chemotherapeutic. VAL-083 has accessed over 40 Phase I and Phase II clinical trials sponsored by the National Cancer Institute (NCI).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Kintara Therapeutics Inc stock information, including NASDAQ:KTRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, KTRA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading KTRA stock methods without spending real money on the virtual paper trading platform.